

1FW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Yusuf K. HAMIED et al.

Confirmation No.: 7990

Application No.: 10/026,949

Art Unit: 1624

Filed: December 27, 2001

Examiner: Brenda Libby COLEMAN

For: PHARMACEUTICAL COMPOSITIONS

CONTAINING NEW POLYMORPHIC FORMS

OF OLANZAPINE AND USES THEREOF

Customer No.

26694

PATENT TRADEMARK OFFICE

Request for Corrected Filing Receipt

Mail Stop: Office of Initial Patent Examination

Filing Receipt Corrections

Commissioner for Patents P. O. Box 1450

Alexandria, VA 22313-1450

Attention: BOX PATENT APPLICATION

Sir:

Submitted herewith is the marked-up copy of the Updated Filing Receipt and a copy of the Declaration with a request that a Corrected Filing Receipt be issued correcting the inventors address:

-- Dharmaraj R. Rao, Mah, JAPAN, <u>INDIA</u> --

We ask that the inventor address be corrected as listed above on the Patent issuing from this application.

Respectfully submitted,

Date: November 14, 2005

Keith G. Haddaway, Ph.D.

Registration No. 46,180 VENABLE LLP

P.O. Box 34385

Washington, D.C. 20043-9998 Telephone: (202) 344-4000

Telefax: (202) 344-8300



VENABLE, BAETJER, HOWARD AND CIVILETTI, LLP

Page 1 of

COMPUTER UPDATED

COMMISSIONER FOR PATENTS UNITED STATES PATENT AND TRADEMARK OFFICE WASHINGTON, D.C. 20231 www.uspto.gov

IND CLAIMS DRAWINGS TOT CLAIMS FIL FEE REC'D ATTY.DOCKET.NO GRP ART UNIT FILING DATE APPLICATION NUMBER 33396-19 954 12/27/2001 1624 10/026.949 🗸 177202

CONFIRMATION NO. 7990

UPDATED FILING RECEIPT

OC000000007705133

Date Mailed: 03/25/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

26694

P.O. BOX 34385

WASHINGTON, DC 20043-9998

Yusuf K. Hamied, Mah, INDIA; Rajendra N. Kankan, Mah, INDIA; Dharmaraj R. Rao, Mah, JAPAN; INDIA

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CIP OF 09/540,749 03/31/2000 PAT 6,348,458

Foreign Applications

INDIA 972/BOM/1999 12/28/1999 INDIA 977/BOM/1999 12/28/1999

If Required, Foreign Filing License Granted 01/23/2002

Projected Publication Date: 07/04/2002

Non-Publication Request: No

Early Publication Request: No

Title

Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof

Preliminary Class

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, urless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

DECLARATION FOR UNITED STATES PATENT APPLICATION
WER OF ATTORNEY, DESIGNATION OF CORRESPONDENCE ADDRESS

Attorney Docket 33396-177202

As a below named inventor, I hereby declare that my residence, post office address and citizenship are as stated below next to my name, and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled https://prescription.org/PHARMACEUTICAL COMPOSITIONS CONTAINING NEW POLYMORPHIC FORMS OF OLANZAPINE AND USES THEREOF, the specification of which

 [] is attached hereto. [x] was filed on December 27, 2001. [] was filed under the Patent Cooperation Treaty on America being designated, and was amended on 	Serial No [if applicable].	the United States of
Amicrica comp accignate -,		

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, 1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code §119(a)-(d) of §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed
972/BOM/1999	India	December 28, 1999	Yes
977/BOM/1999	India	December 28, 1999	Yes

I HEREBY CLAIM the benefit under Title 35, United States Code §119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, §120 of any United States application(s), or §365(c) of any PCT International application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code §112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56 which became available between the filing date of the prior application and the national or PCT International filing date of this application.

U.S. Patent	PCT Patent	Patent	Parent
Application Number	Application Number	Filing Date	Patent Number
09/540,749		March 31, 2000	



Attorney Docket: 33396-177202

Page 2 of 2

DECLARATION FOR UNITED STATES PATENT APPLICATION POWER OF ATTORNEY, DESIGNATION OF CORRESPONDENCE ADDRESS

I hereby appoint the registered attorneys and agents of VENABLE associated with the following customer number to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:



PATENT TRADEMARK OFFICE

VENABLE is located at Suite 1000, 1201 New York Avenue, N.W., Washington, D.C. 20005-3917, Telephone: (202) 962-4800, Telefax: (202) 962-8300. Address all correspondence to VENABLE, Post Office Box 34385, Washington, D.C. 20043-9998.

The undersigned hereby authorizes the registered U.S. attorneys and agents identified herein to accept and follow instructions from the undersigned's assignee, if any, and/or, if the undersigned is not a resident of the United States, the undersigned's domestic attorney, patent attorney or patent agent, as to any action to be taken in the Patent and Trademark Office regarding this application without direct communication between U.S. attorneys and the undersigned. In the event of a change in the person(s) from whom instructions may be taken, the registered U.S. attorneys and agents identified herein will be so notified by the undersigned.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Sole or First Joint Inventor: Yusuf K. HAMIE

Date: <u>January 18, 2002</u>

Citizenship: India

Residence and Post Office Address: Windsor Villa, 2nd Floor, Westfield Estate, Bhulabhai Road, Mumbai 400026 Mah., India

Date: Jan - 18; 2001. Second Joint Inventor: Rajendra N. KANKAN

Citizenship: India

Residence and Post Office Address: A-3/5, N.B.D. Society, NSS Road, Ghatkopar, Mumbai 400084, Mah., India

Signature: Third Joint Inventor: Dharm

Date: Jan 18 2582

Citzenship: India

Residence and Post Office Address: 204 Shriji Krupa Swaminarayannagar, Pokharan Road #1, Thane 400601, Mah., India